4D pharma plc Enters Into Clinical Collaboration Agreement With MSD Investigating the Combination of KEYTRUDA® (pembrolizumab) and MRx0518 in Patients With Solid Tumours
LEEDS, England, June 7, 2018 /PRNewswire/ -- 4D Pharma (AIM: DDDD) today announced an agreement with a subsidiary of MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) to conduct a clinical trial evaluating the combination of KEYTRUDA(R) (pembrolizumab), an anti-PD-1 therapy marketed by MSD, and 4D pharma's live biotherapeutic candidate MRx0518 in patients with solid tumours.
4D pharma plc is a clinical stage biopharmaceutical company, pioneering the development of Live Biotherapeutic Products (LBPs).
MRx0518, 4D's lead oncology programme, has shown therapeutic potential in a variety of tumour types in pre-clinical models and has the potential for synergy in combination with checkpoint inhibitor therapies. The phase I study will evaluate safety, tolerability and preliminary clinical benefit of the combination of KEYTRUDA with MRx0518 in patients who progressed on prior PD-1 inhibitor therapy with renal, bladder, melanoma and non-small cell lung cancer.
"At 4D we believe there is strong scientific rationale for evaluating our lead oncology programme MRx0518, in combination with a checkpoint inhibitor," said Duncan Peyton, founder and CEO of 4D pharma plc. "We are excited to work with MSD and look forward to collaborating on this project."
About 4D pharma
Founded in February 2014, 4D is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform that rationally identifies novel bacteria that have a precise and evolved therapeutic effect. All of 4D's live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The company has its own GMP certified manufacturing facilities and a portfolio of over 300 granted patents. 4D has completed a phase I study in Irritable Bowel Syndrome and has recently completed dosing in a phase I study in Paediatric Crohn's Disease. It currently has a pipeline of 13 pre-clinical programmes, covering disease areas such as cancer, poorly controlled asthma, autoimmune and CNS disease, and plans to commence four additional clinical studies in 2018.
KEYTRUDA(R) is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA.
4D Pharma plc Duncan Peyton, Chief Executive Officer: +44(0)113-895-0130
Zeus Capital Limited - Nomad and Joint Broker Dan Bate / Jordan Warburton +44(0)161-831-1512
Bryan Garnier & Co. Limited - Joint Broker Dominic Wilson/ Phil Walker +44(0)20-7332-2500
SOURCE 4D Pharma PLC
Company Codes: LSE:DDDD